Vested
PE 12
Yield 4.4% ( increasing to 6% ? )
1H, 2011Rev +9%
Profit +22%
EPS growth +0%
Thus far, none of Lansen’s products are subject to any price adjustments and the impact of the price control policies on the autoimmune rheumatic market was relatively small, compared to other pharmaceutical sectors.
For the six months ended 30 June 2011, the overall
gross profit margin of the Group was
61.5% (30 June 2010: 65.4%), representing a decrease of approximately 3.9% over the same period last year.
The
decrease in gross profit margin was mainly attributable to:
(1) the increase in
raw material and packing material prices as compared to the same period last year, resulting in an increase in production costs;
(2) the promulgation of more regulatory requirements and quality standards by the State Food and Drug Administration. Therefore, our production costs increased as the Group was required to enhance the quality of certain products and upgrade its technology; and
(3) in addition, the imposition of city construction tax and an educational tax surcharge by the state caused an increase in cost of sales, and in turn, a decrease in gross profit margin.
Interim dividendThe Directors recommend the payment of an interim dividend of HK8.05 cents (30 June 2010: nil) per share for the six months ended 30 June 2011 to the shareholders listed in the register of members of the Company on 14 September 2011.
The interim dividends will be distributed on or about 23 September 2011 to the shareholders.
http://www.hkexnews.hk/listedco/listcon ... 825502.pdf
It's all about "how much you made when you were right" & "how little you lost when you were wrong"